







CASTLEMAN DISEASE - HOW MANY?

FALKO FEND

INSTITUTE OF PATHOLOGY AND REFERENCE CENTER FOR HEMATOPATHOLOGY TÜBINGEN UNIVERSITY
HOSPITAL AND COMPREHENSIVE CANCER CENTER
TÜBINGEN, GERMANY

APOYO













DISCLOSURES



Research support from Menarini/Stemline

Speaker honoraria from Stemline, Astra Zeneca and EUSAPharma



















LOCALIZED MEDIASTINAL LYMPH-NODE HYPERPLASIA RESEMBLING THYMOMA


Cancer 1956; **9** (4): 822–30.




BENJAMIN CASTLEMAN, M.D., LALLA IVERSON, M.D., AND V. PARDO MENENDEZ, M.D.

Description of 13 patients (aged 19-54) with mediastinal masses

Initially interpreted as thymoma, recognized as form of benign lymph node hyperplasia (6 pages of pictures, no abstract, 5 references)







http://www.iapcentral.org





















HYALINE-VASCULAR AND PLASMA-CELL TYPES OF GIANT LYMPH NODE HYPERPLASIA OF THE MEDIASTINUM AND OTHER LOCATIONS

Cancer 1972 29(3):670-83.



ALBERT R. KELLER, MD,* LISELOTTE HOCHHOLZER, MD,† AND BENJAMIN CASTLEMAN, MD[‡]

Detailed study of 81 cases

- Designation of hyaline vascular and plasma cell type (7 cases) previously recognized by other authors (JA Flendrig 1969)
- Description of seminal features of the 2 subtypes
- How did the concept evolve in the last 50 years?

HV CD	PC CD
Single mass	Multiple lymph nodes
Sometimes satellite lymph nodes involved	Remnant lymph node architecture
Typical regressed GC	Regressed GC rare (2/7)
"Onion skin" appearance	Hyperplastic follicles
No/few plasma cells	Massive plasma cell sheets
Local symptoms (3% systemic sy.)	Systemic symptoms common (50%)
Good prognosis	Fever, anemia, elevated ESR, hypergamma-globulinemia, leukocytosis



















DIAGNOSIS OF CD – A CASE-BASED APPROACH



CASE 1

20-year-old male

Increasing cervical lymphadenopathy over the last two years, otherwise healthy

Status post *Borrelia* infection

Whole body CAT scan: localized right-sided cervical lymphadenopathy, otherwise normal

BM biopsy not performed

Lab findings: normal PB counts and differential, CRP, liver enzymes, LDH, β2-MG, total protein, electrolytes, etc. in normal range

Excision of a cervical node 3.5x2.5 cm












































Anatomical separation into (abnormal) B cell follicles and interfollicular T-cell area


No lymph node sinuses



Expanded CD23/IgD+ follicle mantles

Sometimes multiple regressed GC per follicle

Condensed FDC networks and reduction in GC B cells



DIAGNOSIS: UNICENTRIC CD, HYALINE-VASCULAR TYPE





Additional features


Clusters of plasmacytoid dendritic cells (CD123+, TCL1+)

Aberrant expression of CD5 (Liu Q et al, Histopathol 2013)

Presence of TdT+ T-precursor cells (Ohgami et al, AJSP 2012)

























UNICENTRIC CD



Most common form of CD (70-90%), usually of hyaline-vascular type (70-90%)


May affect several neighboring LNs

Children and (young) adults

Mediastinum most common localization (70%)

Systemic symptoms rare (paraneoplastic pemphigus, bronchiolitis obliterans), usually remit after surgical excision

DFS 91% after 10 years



(Ann Surg 2012;255:677–684)

DIFFERENTIAL DIAGNOSIS

- Reactive lymph node with regressed germinal centers
- •Multicentric Castleman disease, HHV8associated
- •Idiopathic multicentric Castleman disease
- •Marginal zone B-cell lymphoma
- Follicular lymphoma
- •Mantle cell lymphoma with mantle zone growth pattern





















International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease




⑤ blood advances 8 DECEMBER 2020 • VOLUME 4, NUMBER 23

Table 2. Conditions that can overlap with UCD

EBV, Epstein-Barr virus; NHL, non-Hodgkin lymphoma.

Condition Infectious diseases HIV-related adenopathy **Syphilis** EBV infection Inflammatory pseudotumor Neoplasia Hodgkin lymphoma NHL (follicular, marginal zone, mantle cell, lymphoplasmacytic) **FDCS** Plasmacytoma Autoimmunity/other Systemic lupus erythematosus, rheumatoid arthritis, Felty's syndrome Follicular hyperplasia Autoimmune lymphoproliferative syndrome HHV-8-associated MCD or iMCD















UNICENTRIC CD - ETIOLOGY



Absence of abnormal lymphocyte populations, no B-/T-cell clonality, no viruses

Disorder of follicular dendritic cells with dysplasia (?), clonal cytogenetic abnormalities

Clonality by HUMARA assay detected in 22/28 HVCD, but no B- or T-cell clonality*

Increased production of VEGF and expression of EGFR by follicular dendritic cells

PDGFRB mutations detected in 17% of UCD

Recent study** failed to detect mutations in 15 UCD cases with 405 gene panel, CNV involving PTPN6, ETS1 and TGFBR2 in 2 cases (1 UCD and 1 iMCD)

*Chang KC et al, Mod Pathol 2014; **Nagy A et al, Blood Adv 2018; #Li Z et al, Leukemia 2019




















CASE 2: 54-YEAR OLD MALE, ABDOMINAL DISCOMFORT 6 CM MASS IN MESENTERY
















































IMMUNOPHENOTYPE


Positive:


Clusterin, fascin, podoplanin, CD23-/+, CXCXL13

Negative:

CD21, S100, CD35, SMA, Desmin, CD117, ALK

EBV, HHV8











DIAGNOSIS: FOLLICULAR DENDRITIC CELL SARCOMA ARISING IN UCD



Mostly low grade sarcoma with localized disease and rare metastasis

- Variable expression of FDC markers (CD21, CD23, fascin, CD35)
- Variable admixture of benign lymphocytes
- Mutation profile little known

Differential diagnosis

- GIST
- Inflammatory pseudotumor/inflammatory myofibroblastic tumor
- High grade sarcoma, NOS
- Non-specific chronic inflammation with fibrosis
- Retroperitoneal fibrosis




















58 year-old male

2001: proteinuria, night sweats

CT scans: hepatosplenomegaly, abdominal lymphadenopathy

Serology: IgG 17g/L (elevated), IgA: 7.86 g/L (elevated), IgM 1.61 g/L (normal)

A lymph node biopsy was performed.











































DIFFERENTIAL DIAGNOSIS



Nodal marginal zone lymphoma Lymphoplasmacytic lymphoma Multicentric CD, plasma cell variant

















IDIOPATHIC MULTICENTRIC CD

Generalized LAP with preserved architecture and regressed GC


Interfollicular increase in polytypic PC

Polytypic plasmacytosis in BM

EBV and HHV8 negative

iMCD may show any histological subtype

17-49% (!)
hyaline vascular type
46-77% plasma cell type
4-20% mixed type





23 year-old female

2005, 2006, 2007: recurrent Bell's palsy (periods of two months each time with spontaneous resolution)

2013: chest pain, increasing in intensity over weeks.

Severe microcytic anemia (Hb 63 g/L), ESR:128, CRP:111 mg/L, IgG:40,1 g/L (elevated), IgA:5,35 g/L (elevated), IgM:1,48 g/L, IgG4:1,77 g/L (elevated)

Imaging: large mass at the anterior aortic root causing aortic compression and pulmonary artery compression. Invasion in the pulmonary artery was also present. There is also some mediastinal lymphadenopathy

Mini-thoracotomy with biopsy of the mass


















CASE 4 HISTOLOGY






CD20+ B-cells confined to the follicles with interspersed CD3+ T-cells

Plasma cell immunophenotype : CD138+, IgK/IgL:5/1, IgG+, IgG4+(5-10%), IgA-, IgM-

HHV8-, EBV- no B-cell clone detected

Diagnosis: likely MCD, PC variant



IDIOPATHIC MULTICENTRIC CD



Multisystem, frequently life-threatening disease with hyperinflammatory syndrome

- Fever
- Weight loss
- Anasarca
- Generalized small-volume LAP
- Anemia, hypoalbuminemia
- Renal impairment

Rare (2.5-25/million person years), male preponderance, ratio to HHV8/KSHV-associated MCD depends on endemicity

Excisional lymph node biopsy AND correlation with clinical features required for diagnosis

Differential Diagnosis

- Lymphadenopathy with reactive plasmacytosis
- IGG4-related lymphadenopathy

Exclusion criteria

Infection-related disorders

- Kaposi sarcoma herpesvirus infection
- Epstein–Barr virus-associated lymphoproliferative disease
- Inflammation and adenopathy by other infection

Autoimmune or inflammatory diseases

- Systemic lupus erythematosus
- Rheumatoid arthritis
- Adult-onset Still disease
- Juvenile idiopathic arthritis
- Autoimmune lymphoproliferative syndrome

Malignant lymphoproliferative diseases

- Lymphoma
- Multiple myeloma
- Primary lymph node plasmacytoma
- Follicular dendritic cell sarcoma
- POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes) syndrome





















TAFRO SYNDROME AND IMCD



TAFRO (thrombocytopenia, ascites, reticulin fibrosis, renal dysfunction, organomegaly)*

considered to be an **aggressive variant of iMCD**, despite significant clinical differences

- Very aggressive clinical course
- Thrombopenia
- No/rare hypergammaglobulinemia
- Renal dysfunction with intravascular coagulation and fibrinolysis
- Hyaline-vascular or mixed morphology

Table 3. Diagnostic criteria for iMCD-TAFRO

Criteria

Histopathological criteria: need all

Typical LN pathology (atrophic GCs with enlarged nuclei of ECs, proliferation of endothelial venules, small numbers of mature PCs)

Negative LANA-1 for HHV8

Major criteria: need 3 of 5

Thrombocytopenia (<100 000/μL)

Anasarca (pleural effusions and ascites on CT)

Fever (>38°C)

Reticulin fibrosis

Organomegaly

Minor criteria: at least 1

Hyper/normoplasia of megakaryocytes

High alkaline phosphatase without markedly elevated transaminases





















^{*}Masaki Y et al, J Clin Exp Hematop 2013, Takai et al, Rinsho Ketsueki 2010


PATHOGENESIS OF IMCD

Cytokine storm with overproduction of IL-6 and VEGF

T-cell activation?

mTOR, JAK-STAT and type I interferon signaling?

SNP in genes associated with autoinflammation








Dako

IMCD TREATMENT




IL-6 hypercytokinemia is central pathogenetic feature

IL-6-based therapy as first line +/steroids



Management of iMCD Category 1 Evidence Category 2A Evidence Category 2B Evidence Refer to Nonsevere Severe Center of Excellence or Consult Siltuximab + HD Steroids Siltuximab ± Steroids **CD** Expert Tocilizumab ± Steroids Tocilizumab + HD Steroids Rituximab ± Steroids* (1 week, daily assessment) Inadequate Inadequate PR/CR PR/CR Response Response **Continued Therapy** Continued Therapy Rituximab + Steroids Combination Siltuximab ± Steroids ± Immunomodulatory Siltuximab ± Steroids Chemotherapy[†] x1 cycle Agent Tocilizumab ± Steroids Tocilizumab ± Steroids Inadequate Individualized PR/CR **Further Therapy** Response Seek Expert Advice/ Continued Consider **Immunomodulatory Immunomodulatory** Agent ± Steroids Agent*

Van Rhee F et al, Blood Adv 2022



















Dako



48 year-old male

2004: peripheral edema, progressive shortness of breath, peripheral neuropathy

CT scans: splenomegaly and enlarged lymph nodes in peri-aortic, mesenteric, bilateral axillary and inguinal regions.

An axillary lymph node biopsy was performed.

Serology: IgA/Lambda paraprotein

Imaging: Lytic/sclerotic lesions in the vertebra, sacrum and iliac bones

Bone marrow: A small population of IgA/lambda plasma cells































MULTICENTRIC CD, PLASMA CELL VARIANT ASSOCIATED WITH POEMS SYNDROME




Clonal plasma cell disorder (sclerotic PC myeloma, mostly lambda) with range of paraneoplastic symptoms, associated with increased VEGF production

Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal PC disorder, Skin changes

Further symptoms include:

- CD, Plasma cell variant (15-60%)
- Sclerotic bone lesions
- Extravascular volume overload
- Thrombocytosis/Erythrocytosis
- Papilledema
- Abnormal pulmonary function tests

Response to anti-neoplastic therapy





















POEMS SYNDROME DIAGNOSTIC CRITERIA



Table 1. Criteria for the diagnosis of POEMS syndrome

	Criteria/other symptoms and signs	Affected, %*
Mandatory major criteria (both required)	Polyradiculoneuropathy (typically demyelinating)	Dispenzieri A, Blo
	2. Monoclonal plasma cell disorder (almost always λ)	100†
Other major criteria (1 required)	3. Castleman disease‡	11-25
	4. Sclerotic bone lesions	27-97
	5. VEGF elevation§	
Minor criteria (1 required)	6. Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)	45-85
	7. Extravascular volume overload (edema, pleural effusion, or ascites)	29-87
	8. Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)	67-84
	Skin changes (hyperpigmentation, hypertrichosis, glomeruloid hemangiomata, plethora, acrocyano flushing, white nails)	sis, 68-89
	10. Papilledema	29-64
	11. Thrombocytosis/polycythemia¶	54-88
Other symptoms and signs	Clubbing, weight loss, hyperhidrosis, pulmonary hypertension/restrictive lung disease, thrombotic diatheses, diarrhea, low vitamin B_{12} values	

The diagnosis of POEMS syndrome is confirmed when both of the mandatory major criteria, 1 of the 3 other major criteria, and 1 of the 6 minor criteria are present. *Summary of frequencies of POEMS syndrome features based on largest retrospective series.^{2,7-11}





















HHV8-ASSOCIATED MCD




Proliferation of IgM-lambda restricted, polytypic, HHV8-infected plasmablasts in the mantle zone of follicles

Common co-occurrence of Kaposi sarcoma

Increased risk for other HHV8associated lymphoproliferative disorders

- Primary effusion lymphoma
- HHV8+ DLBCL
- HHV8+ germinotropic lymphoproliferative disorder





















HHV8+ MCD: PATHOGENESIS AND CLINICAL FEATURES



Expression of both latent (LANA-1) and lytic (vIL-6, vIRF1) viral proteins in MCD

MCD IgMλ plasmablasts show downregulation of costimulatory molecules (CD40) and IL-10 expression and are detectable in PB

Hypercytokinemia (vIL-6, hIL-6, IL-1, IL-10, TNF) results in systemic symptoms (anemia, fever, hypoalbuminemia)

KSHV inflammatory cytokine syndrome (KCIS) without diagnosis of MCD

Prognosis improved with approriate therapy, worse in HIV infection and with Kaposi sarcoma (>90% 5y OS with Rituximab +/- chemotherapy)

High risk of HHV8-associated lymphoma

Table 3. Summary of the surface phenotype of KIV and conventional plasmablasts

	KIVs	Conventional plasmablasts
CD19	Heterogeneous (~25% positivity)	Uniformly low
CD20	Heterogeneous (~5% positivity)	Negative
CD38	100% high positivity	100% high positivity
lgM	100% high positivity	Heterogeneous (~20% positivity)
κ/λ	Monotypic λ (100% high positivity)	Balanced κ/λ ratio (60/40%)
CD27	Heterogeneous (~25% positivity)	100% high positivity
CD40	Low/negative	Heterogeneous
CD70	Heterogeneous (6% positivity)	Negative
CD86	Heterogeneous (10% positivity)	Mostly positive
CD137L	Negative	Negative
OX40-L	Negative	Negative
ICOS-L	Negative	Negative
BAFF-R	Negative	Negative
PD-L1	Negative	Negative





CASTLEMAN DISEASE

CD is a morphological pattern, but not a clinico-pathological entity


Unicentric CD

- -Hyaline vascular type (>90% of cases)
- -Rare plasma cell type

Multicentric CD

- -HHV8+ MCD, plasma cell (plasmablastic) type
- -MCD associated with POEMS or plasma cell neoplasia (osteosclerotic myeloma)
- -Idiopathic MCD
 - TAFRO subtype of iMCD

Histopathological subtyping is difficult to reproduce and not predictive of response to Siltuximab (Fajgenbaum et al, AJH 2020)





















HOW TO DIAGNOSE CD



Diagnosis of MCD requires a high level of suspicion, appropriate workup and clinical information





Clinical features

- Multi/-unicentric?
- Hyperinflammatory symptoms?
- Autoimmune disorder?
- Plasma cell dyscrasia? Lymphoma?
- HIV?
- EBV or other infections?

Diagnostic tests in (M)CD

- Appropriate immunostaining to rule out lymphoma (AITL, FL, MZL)
- IG heavy and light chains
- **B-cell clonality**
- IgG/IgG4 ratio
- HHV8 (LANA)
- EBV (EBERs)

UCD: mostly typical HV morphology, no systemic sy.

iMCD: usually PC type, polyclonal plasma cells, HHV8-, systemic symptoms

MCD-POEMS/osteosclerotic MM: clonal PC (lambda restricted) in LN and BM

MCD HHV8+: I ANA+ +/- Kaposi sarcoma, mostly in setting of immunosuppression





















REALIZACIÓN







APOYO













